Molecular mechanisms responsible for abnormal endometrial vasculature in women receiving long-acting progestin-only contraceptives (LAPCs) are unknown. We hypothesize that LAPCs impair vascular smooth muscle cell (VSMC) and pericyte proliferation and migration producing thin-walled hyperdilated fragile microvessels prone to bleeding. Proliferating cell nuclear antigen (PCNA) and α-smooth muscle actin (αSMA) double-immunostaining assessed VSMC differentiation and proliferation in endometria from women before and after DepoProvera (Depo) treatment and from oophorectomized guinea pigs (OVX-GPs) treated with vehicle, estradiol (E2), medroxyprogesterone acetate (MPA), or E2+MPA. Wholegenome profiling, proliferation, and migration assays were performed on cultured VSMCs treated with MPA or etonogestrel (ETO). Endometrial vessels of Depo-administered women displayed reduced αSMA immunoreactivity and fewer PCNA (+) nuclei among αSMA (+) cells (P < 0.008). Microarray analysis of VSMCs identified several MPA-and ETO-altered transcripts regulated by STAT1 signaling (P < 2.22 × 10 −6 ), including chemokine (C-C motif) ligand 2 (CCL2). Both MPA and ETO reduce VSMC proliferation and migration (P < 0.001). Recombinant CCL2 reversed this progestin-mediated inhibition, whereas a STAT1 inhibitor abolished the CCL2 effect. Similarly, the endometria of MPA treated OVX-GPs displayed decreased αSMA staining and fewer PCNA (+) nuclei in VSMC (P < 0.005). In conclusion, LAPCs promote abnormal endometrial vessel formation by inhibiting VSMC proliferation and migration.
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progestin contraceptives | abnormal uterine bleeding | VSMC | impaired vascular maturation | proliferation L ong-acting progestin-only contraceptives (LAPCs) are safe, discrete, effective, and can be used by women in whom estrogen use is contraindicated (1, 2) . However, associated abnormal uterine bleeding (AUB) reduces adherence (1) (2) (3) . The endometria of women receiving LAPCs contain elevated levels of VEGF and angiopoietin-2 (Ang-2) (4). Like women, the guinea pig (GP) exhibits spontaneous estrous cycling and hemochorial placentation (5) (6) (7) and is a relevant animal model to study LAPCinduced AUB (1, (8) (9) (10) . In humans and GPs, this hyperangiogenic milieu creates endometria displaying superficial, irregularly distributed enlarged, thin-walled capillaries and venules (2, 9, 10) .
Vascular smooth muscle cells (VSMCs) and pericytes maintain vascular tone, a critical determinant of vessel volume and blood flow (11) . Endothelial cells of arteries and veins are surrounded by VSMCs, whereas those of capillaries are surrounded by pericytes (12) . Completion of angiogenesis requires envelopment of new vessels by pericytes or VSMCs, which express α-smooth muscle actin (αSMA) and tropomyosin (11) (12) (13) .
Currently available LAPCs include Depo-Provera (Depo), an injectable form of medroxyprogesterone acetate (MPA) and Implanon, a subdermally implanted rod that releases etonogestrel (ETO) (3). Women administered LAPCs display significantly reduced endometrial blood flow (14) , consistent with constriction of uterine arteries and arterioles. Although ETO administration constricts GP uterine radial arteries (8) , it paradoxically induces hyperdilation in microvasculature in the functional endometrium (2, 9, 10). We postulate that LAPCs suppress VSMC and pericyte differentiation, proliferation, and migration to create fragile, thinwalled hyperdilated vessels prone to bleed.
Results

Decreased Endometrial VSMC Proliferation in Women Receiving
Depo. VSMC numbers and proliferation index were evaluated in microvessels and spiral arteries of paired endometrial sections from women before and after Depo (injectable MPA) after double-immunostaining for αSMA and proliferating cell nuclear antigen (PCNA). Staining intensity and numbers of αSMA + cells around microvessels ( Fig. 1 A vs . B) and spiral arteries ( Fig. 1 C vs. D) were lower in post-vs. pre-Depotreated endometria (mean ± SEM: 117.8 ± 14.4 vs. 205.8 ± 22.0, respectively; P < 0.008) (Fig. 1E) . The VSMC proliferation index was significantly lower in post-( Fig. 1 B and D) vs. pre-Depo Significance Over a million unintended pregnancies occur in the United States each year because of either discontinuation or misuse of contraceptives. The major reason for discontinuation of longacting progestin-only contraceptives (LAPCs) is the occurrence of abnormal uterine bleeding (AUB). Uncovering the mechanisms underlying LAPC-induced AUB is essential to prevent their discontinuation. We found that LAPCs reduce proliferation of human and guinea pig endometrial vascular smooth muscle cells (VSMCs), resulting in production of thin-walled hyperdilated fragile microvessels. In cultured VSMCs, chemokine (C-C motif) ligand 2 reverses LAPC-mediated inhibition of VSMC proliferation, suggesting that LAPCs impair endometrial vascular integrity and that chemokine ligand 2 administration may prevent LAPC-induced AUB. Fig. 1 A and C) (24.7% ± 3.5 vs. 57.8% ± 6.9; P < 0.003) (Fig. 1F ). (Fig. 2) . Of ETO-modulated genes, 92% (175) are also regulated by MPA (Fig. 2) with the same directional change [i.e., MPA and ETO induce transmembrane protein 119 (TMEM119), a suppressor of myoblast differentiation, and suppress retinoic acid receptor responder (tazarotene induced) 1 (RARRES1), a proliferation inducer] (Tables S1 and S2).
endometria (
LAPC-Regulated Genes
Among MPA-and ETO-regulated genes, H19 imprinted maternally expressed transcript, noncoding RNA (H19), TMEM119, RARRES1, and chemokine (C-C motif) ligand 2 (CCL2) mediate differentiation, proliferation, and migration of VSMCs (15) (16) (17) (18) and were thus chosen for quantitative RT-PCR (qRT-PCR) confirmation. In parallel with the microarray results (Tables S1 and S2), MPA or ETO up-regulated H19 mRNA and TMEM119 mRNA, and down-regulated RARRES1 mRNA and CCL2 mRNA levels (Fig. 2B) . Further evaluation of microarray data by Ingenuity Pathway Analysis (IPA) software predicts that STAT1 inhibition is associated with genes regulated in VSMCs by MPA or ETO (z-score and the overlap P value; −3.06, P < 8.5 × 10 −14 and −2.43,
, respectively) (Fig. 3A) . Confirming this prediction, compared with control VSMCs, Western blotting found that MPA and ETO partially reduced phosphorylated but not total STAT1 levels ( Fig. 3B ).
LAPC Inhibition of VSMC Proliferation Is Reversed by CCL2 via STAT1
Signaling in Culture. In cultured VSMCs, 48-h treatment with MPA or ETO significantly reduced BrdU incorporation vs. control (mean ± SEM 0.31 ± 0.02 or 0.40 ± 0.03 vs. 0.81 ± 0.03 respectively; P < 0.001), whereas P 4 (0.71 ± 0.05) was ineffective (Fig. 4A ). In contrast, none of the progestins altered apoptosis qRT-PCR analysis for regulation of H19, TMEM119, RARRES1, and CCL2 mRNA in cultured VSMC by progestins (B). Bars represent mean ± SEM (n = 3). C, control; P, progesterone (P 4 ).
( Fig. 4B and Fig. S1 ). To determine if inhibition of VSMC proliferation by MPA or ETO is mediated by decreased CCL2 expression, VSMCs were treated with vehicle or MPA or ETO ± recombinant CCL2 (rCCL2) for 72 h. Compared with control (0.86 ± 0.03), rCCL2 elicited a concentration dependent increase in BrdU incorporation (1.05 ± 0.05 and 1.21 ± 0.05, respectively; P < 0.005) (Fig. 4C ). Addition of 10 ng/mL rCCL2 reversed the inhibitory effects of MPA or ETO, whereas 100 μm MTA, a specific STAT1 inhibitor (19) , abolished these rCCL2 effects (Fig. 4C) .
LAPCs Inhibit VSMC Migration in Vitro. Compared with control (migration rate: 48.4%), 12-h incubation with MPA or ETO or P 4 reduced migration of VSMCs (migration rate: 18.7% or 29.6% or 39.4%, respectively; P < 0.001) (Fig. 5) . In coincubations, rCCL2 did not reverse inhibition of VSMC migration by ETO or P 4 , but partially reversed the MPA effect (Fig. 5 ).
MPA Administration Decreases Endometrial VSMC Numbers in
Oophorectomized GPs. Endometrial sections from control, E 2 , E 2 +MPA, or MPA-treated oophorectomized (OVX) GPs were double-immunostained for αSMA and PCNA. Controls displayed moderate to weak discontinuous αSMA immunoreactivity in vessels across the endometrium (Fig. 6 A and B) . In comparison, E 2 -administered GPs displayed elevated numbers of αSMA immunoreactive VSMCs with intense and continuous immunostaining across the endometrium (Fig. 6 C and D) . Addition of MPA blunted these E 2 effects and resulted in discontinuous αSMA immunostaining along vessels in the basal layer (Fig. 6 C vs. E) and absence of immunoreactive cells around superficial layer vessels (Fig. 6F) . Similarly, αSMA immunoreactivity was weaker (Fig. 6 A vs. G) and virtually absent around superficial endometrial vessels in GPs administered MPA alone vs. control (Fig. 6 B vs. H) . Semiquantitative evaluation revealed that E 2 elicited higher αSMA histological scoring (HSCOREs) vs. control (mean ± SEM; 212.7 ± 14.6 vs.. 135.2 ± 26.0, P < 0.005) (Fig. 7A) , whereas E 2 +MPA significantly lowered αSMA HSCOREs vs. E 2 alone (116.7 ± 13.84 vs.. 212.7 ± 14.6, respectively; P < 0.005) (Fig. 7A) . Similar effects were observed following administration of MPA alone vs. E 2 alone (83.50 ± 9.0 vs.. 212.7 ± 14.6, respectively; P < 0.001) (Fig. 7A) . In doublestained sections, PCNA + endometrial VSMC numbers are significantly higher in the E 2 vs. control group (mean ± SEM; 36.8% ± 2.7 vs.. 11.2% ± 2.3; P < 0.001) (Figs. 6 A vs. C or B vs. D and 7B). Administration of E 2 +MPA blocked E 2 -enhanced endometrial VSMC proliferation (11.3% ± 2.5 vs. 36.8% ± 2.7, respectively; P < 0.001) (Figs. 6 C vs. E or D vs. F and 7B). Administration of MPA alone vs. E 2 produced similar effects (10.2% ± 2.8 vs. 36.8% ± 2.7, respectively; P < 0.001) (Figs. 6 C vs. G or D vs. H and 7B).
Discussion
The endometria of women receiving LAPCs display irregularly distributed hyperdilated thin-walled vessels with deficient basement membranes that are the site of AUB (14, 20) . This study This accounts for the hyperdilated microvessels in the superficial endometrium, which are devoid of normal VSMC layer and exhibit increased susceptibility to bleeding. Previous studies investigated VSMC characteristics in the endometrium of normal cycling and LAPC-treated women (21) (22) (23) . As an early differentiation marker, αSMA is expressed by VSMCs of endometrial vessels, by pericytes attached to capillaries, and by stromal myofibroblasts (21, 22) . Increased αSMA expression during the secretory phase (22) suggests a correlation between endometrial vascular maturation with αSMA expression. In support of this thesis, the VSMC proliferation index (24) and the number of endometrial vessels enveloped by more than one VSMC layer increases from the proliferative to secretory phase (25) . Moreover, αSMA expression is decreased around endometrial microvasculature of Norplant users exhibiting bleeding (23) . Building upon these prior reports, PCNA and αSMA doubleimmunolabeling now reveals a significant decrease in endometrial VSMC proliferation index, accounting for the reduction in VSMC numbers, reduced vascular wall thickness, and impaired structural integrity responsible for the hyperdilated thin-walled endometrial vessels seen in women receiving Depo. These pathological changes are consistent with lower VSMC proliferation in menorrhagic vs. normal endometrium (24) . In mice, vascular leakage and bleeding from enlarged, thin-walled capillaries results from pericyte depletion caused by knockout of PDGF subunit B or PDGF receptor β genes (26, 27) , indicating the crucial role played by pericyte/ VSMCs in maintaining vascular integrity.
Given the lack of availability human endometrial VSMCs, we used progesterone receptor-expressing VSMCs isolated from human female aortas (28). Our results revealed both common and unique responses of VSMCs to P 4 , ETO, and MPA. Strikingly, we found much greater numbers of genes modulated by MPA compared with ETO or P 4 . This strong impact of MPA on gene regulation likely accounts for its greater local and systemic effects. However, we focused on common genes regulated by ETO and MPA because AUB is a common side-effect seen in most LAPC users. Thus, we confirmed mRNA levels of H19 (15), TMEM119 (17), RARRES1 (18), and CCL2 (16) because these genes are known to mediate VSMC differentiation, proliferation, and migration.
The present study demonstrates in situ inhibition of endometrial VSMC proliferation in post-Depo users, and in VSMC monolayers treated with MPA or ETO. This inhibition occurs in parallel with down-regulation of CCL2 by both progestins. Conversely, induction of VSMC proliferation by CCL2 (16, 29) suggests that this cytokine could act as an adjuvant treatment to reverse LAPC inhibition of VSMC proliferation. This strategy is supported by the current finding that rCCL2 reverses MPA and ETO mediated inhibition of VSMC proliferation in vitro.
Results of IPA and immunoblotting demonstrated that MPAand ETO-suppressed STAT1 signaling mediates inhibition of VSMC proliferation. In support of this mechanism, the STAT1 inhibitor, MTA, abolishes proliferative effects of CCL2 on progestin-treated VSMCs. These observations are consistent with reports that: (i) the CCL2 receptor CCR2 is present in human and rat VSMCs (30, 31) , (ii) STAT1 signaling induces VSMC proliferation (32) , and (iii) CCR2 activates STAT1 signaling (33) .
Compared with other rodents, GPs share multiple reproductive tract anatomic and physiologic characteristics with humans (6, 7). Our previous studies (8, 9) demonstrated that, as in human endometria, LAPC administration to GPs results in such endometrial vascular changes as focal hemorrhage, increased oxidative stress, high apoptotic indices, and elevated lipid peroxidation. Similarly, as in endometria of women receiving Depo, the present study confirmed reduced numbers of αSMA (+) cells and decreased VSMC Fig. 5 . LAPCs reduces VSMC migration. VSMCs treated with vehicle (control) or P 4 or ETO or MPA in the presence or absence of 10 ng/mL rCCL2 seeded on insert transwell membranes and allowed to migrate to lower wells for 12 h. Bars represent mean ± SEM, n = 3 with three replicates in each independent experiments; *P < 0.05 and # P < 0.001. proliferation in MPA-treated GP endometria, and confirms that in GPs treated with MPA, the majority of superficial endometrial vessels are devoid of VSMCs. Although decreased proliferation and migration or increased apoptosis may contribute to the decreased density of the VSMC layer observed in the superficial endometria of LAPC users, we now show that apoptosis is unlikely to contribute to this abnormal vasculature because the apoptotic index was unaffected by MPA or ETO or P 4 . The partial reversal of MPA but not ETO or P 4 effects on VSMC migration by rCCL2 is likely a consequence of the mixed progestin-glucocorticoid properties of MPA vs. ETO, a purer progestin, or P 4 . Alternatively, the greater number of genes regulated by MPA compared with ETO or P 4 may mediate this partial reversal.
In conclusion, our results reveal that LAPCs induce AUB by unique molecular and cellular mechanisms that impair endometrial VSMC proliferation, migration, or differentiation, and thus produce insufficient VSMCs to maintain vascular integrity. This novel process accounts for emergence of the thin-walled hyperdilated fragile vessels and focal hemorrhage seen in the endometria of LACP users (Fig. 8) . Our results also suggest that coadministration of CCL2 may prevent LAPC-induced AUB.
Materials and Methods
Tissues. After receiving written informed consent at New York University under Institutional Review Board approval, paraffin sections were derived from banked paired endometrial tissues obtained before and after Depo therapy by Pipelle biopsy from each reproductive age woman with regular menstrual cycles during the secretory phase (n = 6). Based on our established animal model for LAPC-induced AUB in humans (9), nulliparous adult female pigmented GPs (weighing 525-775 g) were used in experimental procedures conforming to National Health and Medical Research Council Guidelines of Australia and approved by the Animal Ethics Committee of The University of Western Australia. GPs (n = 24) were subjected to bilateral OVX and given subcutaneous 21-d time-release pellets (Innovative Research of America) containing MPA (2.5 mg/d; n = 6) or 17β-Estradiol (E 2 ) (0.1 mg/d; n = 6), both MPA and E2 (n = 6), or no pellets (n = 6). On day 20 of exposure to the pellets, GPs were killed with pentobarbital and uterine tissues fixed in 10% (vol/vol) formalin and processed for paraffin embedding. In vitro experiments used aortic VSMCs from premenopausal women (n = 2) (Life Technologies).
Immunohistochemistry. Paraffin sections (5 μm) from paired pre-vs. postDepo treated human or GP endometria were deparaffinized, boiled in citrate buffer (pH: 6.0) and then incubated in methanol containing 3% (vol/vol) H 2 O 2 . Following 10% (vol/vol) normal horse serum blocking (Vector Labs), slides were incubated overnight at 4°C with mouse anti-PCNA monoclonal antibody (EMD Millipore). After several rinses in Tris-buffered saline containing 0.1% tween-20 (TBS-T; pH 7.6) slides were then incubated with biotinylated anti-mouse IgG (Vector Labs) for 30 min, then with a streptavidin-peroxidase complex (Elite ABC kit; Vector Labs) for 30 min and with diaminobenzidine (DAB; Vector Labs) for 3 min. These steps, unless otherwise specified, were repeated for double-immunolabeling using 10% (vol/vol) normal goat serum, rabbit anti-αSMA polyclonal antibody for 1 h (Abcam), a goat biotinylated anti-rabbit IgG (Vector Labs), and a streptavidin-alkaline phosphatase (ABC kit) and Vector Red (Vector Labs). For negative controls, normal mouse IgG2a and rabbit IgG were used at the same concentrations as the primary antibodies. Slides were counterstained by Hematoxylin and evaluated by histological scoring (HSCORE), as described previously (34) . (See details for HSCORE evaluation for αSMA immunoreactivity and PCNA quantitation in SI Materials and Methods).
Cell Cultures and Experimental Incubations. VSMCs were thawed and cultured in medium 231(M231; Life Technologies) with smooth muscle growth supplement [5% (vol/vol) FBS; 2 ng/mL human basic fibroblast growth factor, 0.5 ng/mL human epidermal growth factor, 5 ng/mL heparin, 0.2 μg/mL insulin and 5 μg/mL BSA; Life Technologies] with 100 U/mL penicillin, 100 μg/mL streptomycin, 0.25 μg/mL fungizone. Confluent VSMCs were washed twice with 1× PBS to remove residual serum, passaged in 96-well or 6-well plates Fig. 8 . Model of aberrant vascular transformation and related AUB in women administered LAPCs. In normal endometrium, estradiol (E 2 ) and progesterone (P 4 ) regulate angiogenesis as well as VSMC proliferation and migration. Coordination of these steroid-mediated effects triggers vascular maturation resulting in a tight and continuous layer of VSMCs lying beneath endothelial cells of new vessels, which provides normal blood flow to induce endometrial growth. In contrast, long-term effects on human endometrium by synthetic progestins elicit: (i) reduced blood flow which induces local hypoxia; (ii) induced decidualization and increased expression of such angiogenic factors as VEGF, IL8, and Ang-2 in stromal cells; and (iii) inhibited VSMC proliferation and migration by blocking CCL2-mediated STAT1 signaling. The first two mechanisms promote excess angiogenesis, whereas the third mechanism results in insufficient VSMC numbers to cover and surround newly formed vessels. Consequently, impaired vascular maturation generates thin-walled hyperdilated fragile vessels which are prone to leakage and AUB. Fig. 7 . Semiquantitative analysis of αSMA and PCNA immunoreactivity in endometrium of OVX GPs. Graphs represents HSCORE values for αSMA expression (A) and percentage of PCNA (+) VSMCs (B). Bars represent mean ± SEM; n = 6 for each group; *P < 0.005 or and incubated in parallel in M231 with 1% (wt/vol) charcoal striped FBS with 0.1% ethanol (vehicle, control) or 10 −7 M MPA (Sigma-Aldrich) or 10 BeadChip (Illumina). Raw data without normalization were analyzed by GeneSpring GX12.5 software (Agilent Technologies-Silicon Genetics). Normalization was performed as described (35) . Genes with a fold-change > 1.25 and a P value < 0.05 were considered differentially expressed. IPA software explored molecular and biological networks related to differentially expressed genes (Qiagen).
Western Blot Analysis. To confirm inhibition of STAT1 signaling in LAPCtreated VSMCs, detected by IPA, cell lysates from VSMCs were run in 10% (wt/vol) Tris·HCl gel (Bio-Rad). Transfer onto membrane, blocking, washing, chemiluminescence development, and stripping/reprobing were performed as described previously (35) . The membrane was incubated with antitotal STAT1 or antiphospho-STAT1 rabbit monoclonal antibodies (Cell Signaling) and then with peroxidase-conjugated goat anti-rabbit IgG (Vector Labs). Signals were developed by a chemiluminescence kit (GE Healthcare).
qRT-PCR. For qRT-PCR, 500 ng total RNA from each treatment was reverse transcribed by using RETROscript kit (Ambion). qRT-PCR was performed using the TaqMan Gene Expression Assay Kits for H19, TMEM119, RARRES1, and CCL2 (TaqMan ID # Hs00262142_g1, Hs01938722_m1, Hs00161204_m1 and Hs00234140_m1, respectively; Life Technologies) as described previously (36) . Expression of the target mRNAs was normalized to β-actin levels, and the 2 −ΔΔCT was used to calculate relative expression levels.
Transwell Insert Migration Assays. VSMCs (75,000 cells/200 μL) were suspended in M231 containing 1% charcoal striped FBS and either 0.1% ethanol (vehicle control) or the corresponding steroids and seeded onto insert wells (transwell filter with 12-μm pores; EMD Millipore). The inserts were then placed in 24-well plates containing 500 μL M231 with 1% charcoal striped FBS. Statistical Analysis. HSCOREs were normally distributed with equal variance between comparison groups and compared by Student's t-test. Western blot or qRT-PCR results were normally distributed as determined by KolmogorovSmirnov test and analyzed by one-way ANOVA followed by testing post hoc Holm-Sidak method using SigmaStat v3.0 software (Systat Software). A P value < 0.05 is accepted as statistically significant.
